Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PATRIOT: ATR inhibitor monotherapy in advanced solid tumors

Kevin Harrington • 27 Sep 2019
ESMO 2019
General Ceralasertib
PATRIOT

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, discusses the PATRIOT trial (NCT02223923), a Phase I study to assess the tolerability, safety and biological effects of the ATR inhibitor AZD6738 as a monotherapy and in combination with palliative radiation therapy in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kevin Harrington

Novel cell-death targets to enhance chemoradiation in head and neck cancer
2:21
Novel cell-death targets to enhance chemoradiation in head and neck cancer
Kevin Harrington • 20 Oct 2025
Head and neck cancer at ESMO 2025: OrigAMI-4, ASPEN-04, and CompARE
2:59
Head and neck cancer at ESMO 2025: OrigAMI-4, ASPEN-04, and CompARE
Kevin Harrington • 20 Oct 2025
ASPEN-03: evorpacept & pembrolizumab in unresectable, PD-L1+ R/M HNSCC
2:08
ASPEN-03: evorpacept & pembrolizumab in unresectable, PD-L1+ R/M HNSCC
Kevin Harrington • 20 Oct 2025
ASPEN-04: evorpacept with pembrolizumab & chemotherapy in R/M HNSCC
3:04
ASPEN-04: evorpacept with pembrolizumab & chemotherapy in R/M HNSCC
Kevin Harrington • 20 Oct 2025

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals